Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials

Journal of Clinical Oncology

Volumn 20, Issue 7, 2002, Pages 1818-1825

  Lens, Marko B ^a   Dawes, Martin ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON-ALPHA; MEDLINE; MELANOMA; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036534376     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.070     Document Type: Article

References (29)

1. An analysis of prognostic factors in 8500 patients with cutaneous melanoma
2. The role of adjuvant therapy in melanoma management
3. Adjuvant therapy in melanoma
4. Update on the role of adjuvant interferon for high risk melanoma
5. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping
6. What's new in the treatment of cutaneous melanoma?
7. Interferons in the treatment of human cancer
8. Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities
9. The alpha interferons: Clinical overview
10. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study
11. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma
12. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
13. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190
14. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
15. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
16. Adjuvant interferon alpha 2b in high risk melanoma: The Scottish study
17. Aim high: Adjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma
18. Results of adjuvant interferon study in WHO melanoma programme
19. Evaluation of efficacy of adjuvant rIFNα2a in melanoma patients with regional node metastases
20. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial
21. Postsurgical adjuvant therapy on melanoma: Evaluation of a 3-year randomised trial with recombinant interferon-alpha after 3 and 5 years of follow-up
22. Interferon-alpha as adjuvant therapy for melanoma: A meta-analysis of the randomised trials
23. Current therapy for cutaneous melanoma
24. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: The need for more evidence
25. Antibodies to interferon-alpha in treated cancer patients: Incidence and significance
26. Technical details of intraoperative lymphatic mapping for early stage melanoma
27. Treating patients with melanoma with interferon
28. Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alpha in malignant melanoma
29. Adjuvant interferon-alpha in malignant melanoma: Current status